

(43) International Publication Date
26 February 2015 (26.02.2015)

(51) International Patent Classification:

A61K 38/17 (2006.01) A23J 1/20 (2006.01)
A61P 3/10 (2006.01)

(21) International Application Number:

PCT/NZ2014/000172

(22) International Filing Date:

22 August 2014 (22.08.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/869,213 23 August 2013 (23.08.2013) US


(71) Applicant: **THE A2 MILK COMPANY LIMITED**
[NZ/NZ]; C/- Simpson Grierson, Level 27, 88 Shortland
Street, Auckland (NZ).(72) Inventor: **CLARKE, Andrew John**; 14 Cleveland Road,
Parnell, Auckland, 1052 (NZ).(74) Agent: **CATALYST INTELLECTUAL PROPERTY**;
Level 5, 111 Customhouse Quay, Wellington, 6011 (NZ).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: BETA-CASEIN A2 AND BLOOD GLUCOSE LEVELS

Figure 1



(57) Abstract: Regulating the level of glucose in the blood of an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. Uses include managing the symptoms of hyperglycaemia and associated conditions including diabetes. The effect is both acute (post-exposure to the composition) and ongoing.